Published in Lancet on October 16, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Genomics and drug response. N Engl J Med (2011) 4.35
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Personalized medicine: hope or hype? Eur Heart J (2012) 1.80
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Insurance coverage policies for personalized medicine. J Pers Med (2012) 1.19
Genetic susceptibility to ischemic stroke. Nat Rev Neurol (2011) 1.12
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 0.97
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol (2011) 0.92
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One (2012) 0.91
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Critical appraisal of ticagrelor in the management of acute coronary syndrome. Ther Clin Risk Manag (2011) 0.85
Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol (2010) 0.85
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr (2010) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J (2012) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med (2012) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes. Core Evid (2011) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Genomics in cardiovascular disease. J Am Coll Cardiol (2013) 0.83
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy (2014) 0.82
The genetics of common variation affecting platelet development, function and pharmaceutical targeting. J Thromb Haemost (2011) 0.82
Genetic substudy of the PLATO trial. Lancet (2011) 0.81
Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther (2011) 0.81
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet (2015) 0.80
Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One (2014) 0.80
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci (2016) 0.80
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol (2012) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart Assoc (2012) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care. BMC Cardiovasc Disord (2013) 0.79
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.79
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg (2015) 0.78
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol (2010) 0.78
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. Hawaii J Med Public Health (2015) 0.78
Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther (2015) 0.78
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. J Atheroscler Thromb (2016) 0.77
Response to antiplatelet treatment: from genes to outcome. Lancet (2010) 0.77
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wien Klin Wochenschr (2011) 0.77
Southern Saskatchewan Ticagrelor Registry experience. Patient Prefer Adherence (2014) 0.77
Personalized genomes and cardiovascular disease. Cold Spring Harb Perspect Med (2014) 0.77
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Br J Clin Pharmacol (2014) 0.77
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J (2015) 0.77
Pharmacogenomic testing and antithrombotic therapy: ready for prime time? Rambam Maimonides Med J (2013) 0.77
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS One (2013) 0.77
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf (2014) 0.76
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. Exp Ther Med (2014) 0.76
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) (2014) 0.76
Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention. Front Pharmacol (2016) 0.75
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
Cardiovascular drugs and the genetic response. Methodist Debakey Cardiovasc J (2014) 0.75
Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome? Nat Rev Cardiol (2012) 0.75
Routine genotyping of patients on clopidogrel: Why the resistance? Indian Heart J (2015) 0.75
Is ticagrelor the antiplatelet therapy panacea? Circ Cardiovasc Genet (2010) 0.75
Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel. Int J Mol Sci (2014) 0.75
Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm (2016) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
Gene-drug interaction in stroke. Stroke Res Treat (2011) 0.75
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. Med Sci Monit (2016) 0.75
Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Mater Sociomed (2011) 0.75
Pharmacogenetics: Clinical response to antiplatelet therapy--how much does genotype count? Nat Rev Cardiol (2010) 0.75
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin (2017) 0.75
Oral antiplatelet therapy in acute coronary syndromes: update 2012. Eur Heart J Acute Cardiovasc Care (2012) 0.75
Exploring predisposition and treatment response--the promise of genomics. Prog Cardiovasc Dis (2012) 0.75
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J (2016) 0.75
Personalized antiplatelet therapy: state of the art. JRSM Cardiovasc Dis (2012) 0.75
A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records. AMIA Jt Summits Transl Sci Proc (2017) 0.75
[Coronary stent thrombosis: what's new in 2011?]. Herz (2011) 0.75
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther (2017) 0.75
The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovasc Drugs Ther (2017) 0.75
A Knowledge-based System for Intelligent Support in Pharmacogenomics Evidence Assessment: Ontology-driven Evidence Representation and Retrieval. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol (2017) 0.75
The dawn of neurosurgery in pre-conquest Mesoamerican territories. Childs Nerv Syst (2017) 0.75
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Eur J Clin Pharmacol (2017) 0.75
Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. J Res Med Sci (2017) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet (2005) 14.30
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation (2010) 4.60
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care (2009) 3.69
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Case/pseudocontrol analysis in genetic association studies: A unified framework for detection of genotype and haplotype associations, gene-gene and gene-environment interactions, and parent-of-origin effects. Genet Epidemiol (2004) 3.39
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med (2011) 3.20
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing. Nat Commun (2012) 3.18
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet (2006) 3.01
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol (2002) 2.87
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation (2009) 2.84
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. JACC Cardiovasc Imaging (2016) 2.36
Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med (2005) 2.32
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet (2012) 2.26
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart (2010) 2.24
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke (2007) 2.22
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med (2010) 2.19
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest (2004) 2.19
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17